The efficacy and safety of observation therapy or terazosin 2mg or 5mg administration for Distal Ureter Stone Patients
Not Applicable
- Conditions
- Diseases of The genitoruinary system
- Registration Number
- KCT0005052
- Lead Sponsor
- Seoul Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 194
Inclusion Criteria
1) Men over 19
2) Those with lower urinary tract stones less than 10mm in diameter
3) A person who voluntarily decides to participate in this study and agrees in writing to the subject consent
Exclusion Criteria
1) People with urinary tract infection
2) A person with a severe hydronephrosis
3) Those who have multiple stones
4) Patients with ureteral stenosis
5) Patients who are currently taking Calcium Channel Blocker or Alpha Blocker
6) Those who are sensitive to alpha-blocker preparations
7) Patients with Systolic blood pressure <110mmHg
8) Patients who has a history of surgery related to the urinary tract
9) Others who are inappropriate to participate in research as judged by the Primary Investigator or other Investigators
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method atural excretion rate of lower urinary tract stones when waiting therapy or terazosin 2mg or 5mg was administered to patients with lower urinary tract stones for 4 weeks
- Secondary Outcome Measures
Name Time Method The average number of days it takes for the lower urinary tract stones to be discharged when observational therapy or terazosin 2 mg or 5 mg is administered for up to 4 weeks to patients with lower urinary tract stones.